Live · 21 Oct 2026 SPX 7,757.17 +0.58% NDX 29,822.52 +1.13% VIX 16.68 -3.64% GOLD 4,141.70 -0.02% CL 97.96 -3.76% BTC 84,013.03 +1.29%
NAS100 29,823 +1.13% S&P 7,757 +0.58% GOLD $4,142 −0.02% BTC $84,013 +1.29% VIX 16.68 −3.64% live tape · as of 23:58 UTC · 21 Oct
Vol. II · No. 295Thursday, 22 October 2026
TTitan Protect
Case Studies · Earnings Echo

A Clean Beat From Abbott Laboratories, and It Holds Up to Our Screen.

Filed Thursday 22 October 2026 · 00:22 UTC · Entry no. 131222 · scored against the close · never edited

A Clean Beat From Abbott Laboratories, and It Holds Up to Our Screen.
Earnings Review · 22 October 2026
The print
Revenue n/a. EPS $1.42 vs $1.41 expected.
How the market took it
On 2026-10-21 the shares closed at $100.51, -1.9% against the prior close of $102.45 (opening -1.1% from the prior close). Option volatility implied a normal one-day swing of about ±1.7%, so a -1.9% close was about what the market implied. Across the last 25 reports the shares have moved an average of +1.4% over the five sessions after the print, so the -1.9% on the day sits behind that average.
What changed versus going in
Earnings came in at $1.42 a share against $1.41 expected, a beat of 1% (+$0.01 a share).
Did the flow confirm the move?
Underlying money flow is neutral (21-day Chaikin Money Flow +0.02, five-day price change -0.2%, as of 2026-10-20, desk flow model): no strong accumulation or distribution signature.
Give the business its due
The business itself is genuinely strong: revenue growing about 13%, net margins near 12%, a moderate competitive moat, backed by a 11% return on equity.
Levels that matter
At $100.51 the shares sit 24% below the 52-week high of $132.03 and 23% above the low of $81.97 (37% of the way up the range). The 50-day average is $105.87, above the price. The 200-day average is $102.53, above the price.
The valuation lens
The shares trade about 21% below our fair-value estimate: a modest cushion. Fair value lands near $127 against a $100.51 share price, a margin of safety of about 21%. The trailing multiple sits around 34 times earnings, which only makes sense if the growth holds.
The ethical lens, our differentiator
Screens compliant (both standards agree). A name values-conscious investors can weigh on the merits.
The verdict for a values-conscious investor
It clears the screen; size it to your own risk and conviction. One quarter, strong or soft, does not decide whether a holding is suitable.

This is analysis, not financial advice. Always manage your risk.

How This Entry Scores

Every level named in a session brief is scored against the next scheduled close. Nothing is edited after filing: if a level breaks, the record shows it as filed, not as corrected. The desk's full scored history sits on the track record page.

Continue Reading View all Case Studies →
Membership

The ledger is public. The desk behind it is not.

Membership opens every room and every entry the day it is filed, with the same dated honesty the record is built on.

Join the desk

This is analysis, not financial advice. Always manage your risk.

Get our weekly market brief free.